SHANGHAI, April 19th, 2024 - IMPACT Therapeutics ("IMPACT"), a biopharmaceutical company focusing on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality, announced the successful completion of its Series D+ financing of RMB 400 million. This round of financing was co-led by GTJA Investment Group and Kingray Capital, with participation from Yangzhou Guojin Group and Guyu Nange, and with continued funding from existing shareholders Lilly Asia Ventures and Xiamen C&D Emerging Industry Equity Investment. Ark Capital is the financial advisor of this financing round.
“We are pleased to announce the successful completion of our Series D+ round of financing and would like to thank our new shareholders as well as our existing shareholders for their support and trust in IMPACT." said Dr. Sui Xiong Cai, Chief Executive Officer of IMPACT. “The proceeds from this round will accelerate the commercialization of Senaparib, the ongoing clinical development of multiple compounds, including the global development of PARP1 selective inhibitors, and the development of multiple early pre-clinical projects. We firmly believe that Senaparib, with the Best-in-class potential, and with the support of our excellent investors, will benefit more ovarian cancer patients soon backed up by the strong marketing network and professional promotion experience of our commercialization partner, Huadong Medicine; we also expect more innovative drug candidates with synthetic lethal targets in our pipeline to show breakthrough potential in future clinical development."
About Senaparib
Senaparib, discovered and developed by IMPACT, is a potent and novel PARP1/2 inhibitor. Its distinctive molecular structure ensures exceptional target selectivity and wide therapeutic window. The Phase Ⅲ registrational study (FLAMES) evaluating Senaparib as a first-line maintenance therapy in advanced ovarian cancer patients (all-comers) has met its primary endpoint. In August 2022, the fixed dose combination capsules of Senaparib and temozolomide for the treatment of adult patients with small cell lung cancer was granted orphan-drug designation by the U.S. Food and Drug Administration (FDA). In August 2023, the National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for Senaparib in China.
About IMPACT Therapeutics
IMPACT Therapeutics is a biopharmaceutical company dedicated to the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality. IMPACT Therapeutics has assembled one of the most comprehensive DNA damage responses (DDR) global pipeline of novel drug candidates generated by in-house discovery efforts and is expanding to other novel synthetic lethality targets to broaden its pipeline. IMPACT’s pipeline products include PARP inhibitor Senaparib (IMP4297), WEE1 inhibitor (IMP7068), ATR inhibitor (IMP9064), and PARP1 selective inhibitor (IMP1734, in collaboration with Eikon Therapeutics), as well as other novel DDR pathway inhibitors.
Source: IMPACT Therapeutics
Related News: